Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676268 | 1.00 | OPRK1 (0.50) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| Hydrochloric Acid SCHEMBL27557899 | 0.98 | SLC6A2 (0.48) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| Hydrochloric Acid SCHEMBL29408495 | 0.98 | SLC6A2 (0.48) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| Hydrochloric Acid SCHEMBL29408473 | 0.98 | SLC6A2 (0.48) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| SCHEMBL6205912 | 0.84 | OPRK1 (0.47) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| SCHEMBL7318710 | 0.83 | OPRK1 (0.50) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| SCHEMBL7318705 | 0.83 | OPRK1 (0.50) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| SCHEMBL7324807 | 0.83 | OPRK1 (0.50) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| Hydrochloric Acid SCHEMBL27290671 | 0.82 | OPRK1 (0.48) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B | |
| Hydrochloric Acid SCHEMBL27290669 | 0.82 | OPRK1 (0.48) | OPRK1SLC6A2SLC6A4SLC6A3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007006585-A2 | SYNTHESIS OF A POROUS AND/OR STRATIFIED STRUCTURE MANGANESE OXIDE | ELSPER RUEDIGER (DE) | 2007-01-18 | — | — | WO | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-113683535-B | Compound containing cyanoguanidine structure and preparation method and application thereof | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-113683535-A | Compound containing cyanoguanidine structure and preparation method and application thereof | 中国药科大学 | 2021-11-23 | — | — | CN | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| CN-1086033-C | Electrophotographic photosensitive member, and electrophotographic apparatus and device unit employing the same | CANON KK (JP) | 2002-06-05 | — | — | CN | disclosed |
| CN-1131285-A | Electrophotographic method using photosensitive material | MITA INDUSTRIAL CO LTD (JP) | 1996-09-18 | — | — | CN | disclosed |
| CN-1079311-A | Electrophtography photosensor and with the equipment and the unit of this photoreceptor | CANON KK (JP) | 1993-12-08 | — | — | CN | disclosed |
| US-4510082-A | NONHABIT-FORMING ANALGESICS | ELI LILLY AND COMPANY (US) | 1985-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | OPRK1 2211/4885SLC6A2 1728/4885SLC6A4 2460/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | OPRK1 78/4885SLC6A2 1029/4885SLC6A4 1046/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | OPRK1 83/4885SLC6A2 65/4885SLC6A4 77/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | OPRK1 2211/4885SLC6A2 1728/4885SLC6A4 2460/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | OPRK1 142/4885SLC6A2 144/4885SLC6A4 330/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | OPRK1 142/4885SLC6A2 144/4885SLC6A4 330/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | OPRK1 2211/4885SLC6A2 1728/4885SLC6A4 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.